Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for patients with solid tumors. The Food and Drug Administration (FDA) approval of ...

The approval of subcutaneous amivantamab allows physicians flexibility in offering treatment for non–small cell lung cancer.

hands of a child with juvenile idiopathic arthritis Researchers evaluated the efficacy and safety of abatacept in pediatric patients with polyarticular-course juvenile idiopathic arthritis. ATLANTA — ...

Martin Dietrich, MD, PhD, a medical oncologist at the Cancer Care Centers of Brevard and an assistant professor at the ...

J&J has hypothesized that subcutaneous absorption of the drug may potentially enhance immune-mediated anticancer activity.

The FDA approves a new subcutaneous formulation of amivantamab, enhancing treatment for advanced lung cancer with reduced administration time and improved safety.

The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...

Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...

Johnson & Johnson JNJ announced that the FDA has approved the subcutaneous (under the skin or SC) formulation of its EGFR/MET ...

A phase 3 trial demonstrated shorter administration times with subcutaneous vs IV delivery of nivolumab with no significant difference in mRCC progression-free survival. Subcutaneous administration of ...

The green light for Rybrevant Faspro – which combines amivantamab with hyaluronidase – means that the drug is the first ...

BCS: Radiological Tests Little Use in Detecting Breast Mets For human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, a subcutaneous formulation of trastuzumab is non-inferior ...